Orion Corporation has signed a long-term license agreement with Amneal Pharmaceuticals to commercialize Amneal’s generic products in Orion territories.
Under the terms of the agreement, Orion is granted exclusive licence to commercialize and sell Amneal’s generic products in most parts of Europe as well as in Australia and New Zealand. The initial portfolio will include a mix of generic products commercially available in the U.S. today, as well as selected pipeline products currently under development. Initial products will be registered throughout Europe, Australia and New Zealand starting in 2023, with launches expected over the coming years.
“This agreement expands our footprint in the European generics market as well as in the Asia-Pacific region.”
“We are delighted to announce this collaboration with Amneal, and we look forward to working together to bring these treatments to patients,” says Liisa Hurme, President & CEO of Orion. “This agreement expands our footprint in the European generics market as well as in the Asia-Pacific region. In addition, it supports our growth strategy and is yet another fine example how Orion grows its business through high-quality strategic partnerships.”
Orion and Amneal will work together to develop and register products to Orion markets.
Photo of Liisa Hurme, President & CEO of Orion
